Improvement of the biocompatibility of alginate/poly‐L‐lysine/alginate microcapsules by the use of epimerized alginate as a coating
- 3 February 2003
- journal article
- research article
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 64A (3), 533-539
- https://doi.org/10.1002/jbm.a.10276
Abstract
Alginate/poly-L-lysine(PLL)/alginate capsules are used widely for the microencapsulation of cells. Alginate consists of guluronic acid and mannuronic acid, the ratio and sequence of which affect the properties of the alginate. Using C5-epimerases, mannuronic acid can be converted to guluronic acid in the alginate polymer. Such an enzyme, AlgE4, was used to convert blocks of mannuronic acid (M-blocks) to blocks of alternating sequence (MG-blocks). The aims of this study were 1) to investigate whether the use of epimerized alginate as a coating could improve the biocompatibility of alginate/PLL/alginate capsules and 2) to study the biocompatibility of simple alginate beads prepared with epimerized alginate. Four different capsules, two of which contained epimerized alginate, were investigated after implantation in C57BL/6 mice for 1 week. The biocompatibility of alginate/PLL/alginate capsules, as measured by retrieval rates of the capsules and DNA contents and glucose oxidation rates of the cellular overgrowth, was improved when an epimerized coating alginate was used. There were, however, no statistically significant differences in the biocompatibility of simple alginate beads made from epimerized alginate when compared with non-epimerized alginate beads. In general, such beads produced without a PLL coating swelled to a higher extent than the conventional alginate/PLL/alginate capsules. In conclusion, the use of an epimerized coating on alginate-PLL-alginate can improve the biocompatibility of such capsules but still cannot completely eliminate the detrimental effects of PLL on the biocompatibility of the capsules. © 2003 Wiley Periodicals, Inc. J Biomed Mater Res 64A: 533–539, 2003Keywords
Funding Information
- BIOMed 5 (QLRT-1999-00034)
- Norwegian Research Council (Program of Medical Technology)
- Swedish Research Council (72X-109, 72X-9237)
- Swedish Diabetes Association
- Novo-Nordisk Insulin Fund
- Family Ernfors Fund
- Juvenile Diabetes Foundation International
- Wallenberg Foundation
This publication has 24 references indexed in Scilit:
- Bioartificial livers (BAL): current technological aspects and future developmentsJournal of Membrane Science, 2001
- Mannuronan C-5-Epimerases and Their Application for in Vitro and in Vivo Design of New Alginates Useful in BiotechnologyMetabolic Engineering, 1999
- Persistent Delivery of Factor IX in Mice: Gene Therapy for Hemophilia Using Implantable MicrocapsulesHuman Gene Therapy, 1999
- Use of Nonautologous Microencapsulated Fibroblasts in Growth Hormone Gene Therapy to Improve Growth of Midget SwineHuman Gene Therapy, 1998
- Alginate polycation microcapsulesBiomaterials, 1996
- A family of modular type mannuronan C‐5‐epimerase genes controls alginate structure in Azotobacter vinelandiiMolecular Microbiology, 1995
- Host Reaction against Empty Alginate-polylysine Microcapsules. Influence of Preparation ProcedureJournal of Pharmacy and Pharmacology, 1993
- Behavioral recovery following intrastriatal implantation of microencapsulated PC12 cellsExperimental Neurology, 1991
- The effect of capsule composition on the biocompatibility of alginate-poly-1-lysine capsulesJournal of Microencapsulation, 1991